Results 61 to 70 of about 3,776 (143)

Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

MedComm, Volume 7, Issue 8, August 2026.
Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge, Dong Han, Jing Wang, Xinyu Dai, Chen Ma, Feihong Chen   +5 more
wiley   +1 more source

Talimogene laherparepvec como terapia oncolítica [PDF]

, 2016
El cáncer es uno de los principales problemas de salud a nivel mundial, y son múltiples las terapias estudiadas y desarrolladas para intentar vencerlo. Entre ellas, la terapia oncolítica constituye un avance prometedor en la lucha contra el cáncer.
Jiménez Núñez, Cristina
core   +1 more source

Updates on intratumoral therapies in melanoma

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related ...
Vincent T. Ma, Alyssa K. Steimle, Janmesh D. Patel, Caroline Burkey, Justin C. Moser, Asad Javed, Hibba tul Rehman, Mustafa Ege Seker, Alexander Birbrair, Orhan S. Ozkan, Mark R. Albertini, Yana G. Najjar, Rajan P. Kulkarni   +12 more
wiley   +1 more source

Triple‐Mutated HSV‐1 Expressing Soluble B7‐1 Plus CTLA‐4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer

Cancer Science, Volume 117, Issue 7, Page 1961-1974, July 2026.
In murine tongue cancer models, T‐mB7‐1, a triple‐mutated oncolytic herpes simplex virus type 1 (HSV‐1) engineered to express soluble B7‐1, suppresses cervical lymph node metastasis and improves survival, addressing a major prognostic determinant in oral squamous cell carcinoma (OSCC).
Akinari Sugauchi, Toshihiro Uchihashi, Hirotaka Ito, Miwako Iwai, Yuzuri Tsurumaki Sato, Kyoko Kurioka, Sena Zeynep Usta, Minoru Tanaka, Mikihiko Kogo, Susumu Tanaka, Hiroshi Fukuhara, Tomoki Todo   +11 more
wiley   +1 more source

CyTOF dataset and Luminex data for paper "Primary prophylaxis with mTOR inhibitor enhances T-cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma"

, 2023
<p>Contains the raw CyTOF FCS files and Luminex excel file for the paper "Primary prophylaxis with mTOR inhibitor enhances T-cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell ...
Obeid, Michel, Joo, Victor
core   +1 more source

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ABSTRACT The 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting took place in Amsterdam, The Netherlands on October 25th, 2025. Several promising drug candidates are in development; however, there is still an urgent need for better prevention, detection, and treatment of uveal melanoma.
Andrew E. Aplin, Katherina Alsina, Allison S. Betof, Joseph Birkett, Marcus O. Butler, George Cole Jr., Rizwan Haq, Florian A. Karreth, Vinit B. Mahajan, Rahul Marpadga, Prithvi Mruthyunjaya, Paul Nathan, Jonas A. Nilsson, Gary Palmer, Joseph J. Sacco, Takami Sato, Sarah Stanhope, Pang‐ning Teng, Kyleigh LiPira   +18 more
wiley   +1 more source

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

, 2019
IMPORTANCE. A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates ...
Cranmer, Lee D, Curiel-Lewandrowski, Clara, Abraham, Ivo, Babiker, Hani M, Almutairi, Abdulaali R, Oh, Mok, Alkhatib, Nimer S, McBride, Ali   +7 more
core   +1 more source

DataSheet_1_Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).docx

, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Erlinda M. Gordon, Walter Andree Tellez, Ania Moradkhani, Chrysler Valencia (15443486), Don A. Brigham (15443498), Chrysler Valencia, Don A. Brigham, Sant P. Chawla, Victoria Chua-Alcala (15443501), Stefan Makrievski, Hripsime Chomoyan, Amir Ahari, Nadezhda Omelchenko, Ania Moradkhani (15443507), Doris Quon (15443504), Victoria Chua-Alcala, Hripsime Chomoyan (15443483), Stefan Makrievski (15443495), Nadezhda Omelchenko (15443492), Amir Ahari (15443489), Doris Quon, Sant P. Chawla (5339396), Walter Andree Tellez (8861582), Erlinda M. Gordon (5339399)   +23 more
core   +1 more source

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Journal for ImmunoTherapy of Cancer, 2017
Background Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response ...
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross   +7 more
doaj   +1 more source

Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy

Aggregate, Volume 7, Issue 6, June 2026.
Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao, Dong Wang, Lei Wang, Hongkai Zhang, Yue Sun, Dan Ding   +5 more
wiley   +1 more source